Maribavir Use & Effectiveness in the Real-World (ARISE)

Objectif(s) de la recherche et intérêt pour la santé publique

Finalité de l'étude

Objectifs poursuivis

Domaines médicaux investigués

Bénéfices attendus

This non-interventional study utilizing secondary data from routine clinical care will be conducted to investigate the use, effectiveness and safety of maribavir in the treatment of Cytomegalovirus (CMV) infection post-transplant in several European countries. The primary objective of this study is to describe the effectiveness of maribavirin terms of viremia clearance and effect duration . Moreover, the study will evaluate maribavir treatment pattern and potential impact on health care resources utilization.
This multinational, non-interventional, retrospective cohort study will utilize existing data from medical records, collected from patient transplant date until start of chart abstraction. Patients are eligible if they have had a CMV infection/disease after solid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT)and have been treated with maribavir as per commercial use or as part of early access programs. .
Documenting early post-approval experience with maribavir in a real-world setting is relevant to characterize the clinical profile of this treatment and to inform future post-transplant CMV management/treatment guidelines.